Evaluating and managing adrenal incidentalomas

ABSTRACT

Adrenal masses that are found incidentally should be evaluated with both imaging and hormonal studies. The attenuation coefficient on noncontrast computed tomography (CT), expressed in Hounsfield units (HU), is better than tumor size in differentiating adrenal adenomas and hyperplastic lesions from nonadenomas. All patients should undergo hormonal evaluation for Cushing syndrome and pheochromocytoma. Those with hypertension should also be evaluated for hyperaldosteronism.

KEY POINTS

Adrenal masses are detected incidentally in up to 5% of patients undergoing abdominal imaging studies. Up to one in five are functional.

Once the radiologic characteristics of an adrenal mass have been taken into consideration, a 6-cm tumor size is a reasonable threshold for surgical resection.

A noncontrast CT attenuation coefficient of less than 10 HU reliably rules out adrenal metastasis and adrenal cortical carcinoma.

There is no good evidence to support continuing radiologic surveillance if the size of the tumor does not increase in 6 to 12 months.

Patients with adrenal tumors with a noncontrast CT attenuation coefficient of 10 HU or less should have a yearly evaluation for hormonal hypersecretion. The optimal duration of follow-up is not known, but the incidence of hypersecretion may plateau after 5 years.

ADRENAL INCIDENTALOMAS: A CLINICAL QUANDARY

Widespread use of imaging tests such as abdominal ultrasonography, CT, and magnetic resonance imaging (MRI) is creating the clinical quandary of what to do about adrenal incidentalomas—masses of 1 cm or larger on the adrenal glands discovered serendipitously on imaging in patients with no symptoms or clinical evidence of adrenal disease. (This definition excludes findings in patients undergoing imaging procedures as part of a cancer workup or staging.)

How can one determine if these lesions are clinically benign or need treatment?

BECOMING EVER MORE COMMON

The prevalence of adrenal incidentalomas ranges from 1.4% to 8.7%, increasing with age. Adrenal incidentalomas are found in
up to 5% of patients undergoing CT of the abdomen,3–5 and as imaging techniques improve, they can be expected to be discovered even more frequently.

### Table 1

<table>
<thead>
<tr>
<th>Cause</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenal cortical tumors</td>
<td></td>
</tr>
<tr>
<td>Adenoma</td>
<td>36–94</td>
</tr>
<tr>
<td>Nodular hyperplasia</td>
<td>7–17</td>
</tr>
<tr>
<td>Adrenocortical carcinoma</td>
<td>1.2–11</td>
</tr>
<tr>
<td>Adrenal medullary tumors</td>
<td></td>
</tr>
<tr>
<td>Pheochromocytoma</td>
<td>1.5–11</td>
</tr>
<tr>
<td>Other adrenal tumors</td>
<td></td>
</tr>
<tr>
<td>Myelolipoma</td>
<td>7–15</td>
</tr>
<tr>
<td>Lipoma</td>
<td>0–11</td>
</tr>
<tr>
<td>Cysts and pseudocysts</td>
<td>4–22</td>
</tr>
<tr>
<td>Hematoma and hemorrhage</td>
<td>0–4</td>
</tr>
<tr>
<td>Infections, granulomas</td>
<td>Rare</td>
</tr>
<tr>
<td>Metastases</td>
<td>0–21</td>
</tr>
</tbody>
</table>


The two major predictors of malignancy are the tumor’s size and its features on imaging.

### Tumor size

Many experts regard size as an important factor in differentiating benign tumors such as adrenal adenomas and hyperplasias from malignant lesions such as adrenal carcinomas and metastases from other primary sites.4,8,9 The larger an adrenal mass, the more likely it is malignant. However, significant overlap exists, and experts disagree about the threshold that should trigger resection of a nonfunctional adrenal tumor: recommendations range from 4 to 6 cm.1,3,7,10

Hamrahian et al (our group),11 in a retrospective review of 299 adrenalectomies in 290 patients and using surgical histopathology as the gold standard, found that even a threshold of 2 cm is not 100% specific in ruling out malignancy. But our data support 6 cm as a reasonable threshold for surgical resection once radiologic characteristics are taken into account.

Many experts also believe that if an adrenal mass does not grow over time, it can reliably be assumed to be benign.7 Only very rarely do masses that do not change in appearance on CT for up to 18 months turn out to be metastases.12 On the other hand, 5% to 25% of nonfunctioning adrenal masses grow at least 1 cm over time.7,13

### Features on imaging studies

The noncontrast CT attenuation coefficient, expressed in Hounsfield units (HU), is increasingly used to differentiate benign adrenal adenomas and hyperplasias from malignant lesions and pheochromocytomas (Figure 1). Water has a value of 0; substances that are less dense than water have negative values while substances that are more dense have positive values. Adipose tissue has a relatively low value, so the lesser the fat content, the higher the attenuation coefficient. Intracytoplasmic fat is often abundant in adrenal adenomas but is rare in adrenal metastases, pheochromocytomas, and adrenal cortical carcinomas.14 Therefore, masses with higher values are more likely to be nonadenomas.

Suggested threshold values range from 0 to 20 HU. A consensus panel of the National Institutes of Health recommended 10 HU,7 a threshold value that our group found to be
100% specific for ruling out nonadenomas in our study,11 which contained the largest body of published data with surgical histopathology as the diagnostic gold standard. In addition, we and others have found the HU value on noncontrast CT to be a better criterion than tumor size for distinguishing adrenal adenomas from nonadenomas.11,15,16

**Enhancement washout** is valuable in differentiating lipid-poor adrenal adenomas (noncontrast HU > 10) from nonadenomas. A CT scan with contrast is performed, the attenuation coefficient of the mass is measured 1 minute after contrast administration and again 15 minutes after contrast administration, and the percentage of enhancement washout is calculated. An absolute enhancement washout percentage of less than 60% at 15 minutes after giving contrast strongly suggests a nonadenoma.17,18

**CT characteristics other than lipid content** may help differentiate adrenal adenomas from nonadenomas: benign lesions tend to have a smooth border, be round or oval in shape, have sharp margins, conform to the shape of the adrenal gland, contain no calcification within or on the edge of the tumor, be homogeneous, and not enhance after contrast. Although these features can help in characterizing a mass and deciding how to manage it, none of them individually enables one to rule out malignancy confidently.14

MRI is as effective as CT in differentiating benign from malignant adrenal masses, but it has no clear advantage over CT except in pregnant women, children, and patients with allergies to contrast.19 On T1-weighted gradient echo images, a drop in signal intensity during “opposed-phase” (out-of-phase) images compared with in-phase images is consistent with high fat content and is highly specific for adrenal adenoma (FIGURE 2).20

Pheochromocytomas can be identified by a very high signal intensity on T2-weighted images, along with no signal loss on opposed-phase vs in-phase T1-weighted images (sensitivity 93%–100%, specificity 88%–98%).21–23

**Adrenal scintigraphy** using iodomethyl-norcholesterol I 131 (NP-59) may also help differentiate benign from malignant adrenal masses larger than 2 cm. Adrenal nonadenomas have no uptake or significantly less uptake than adenomas.24 However, this test is not widely available and takes 5 to 7 days to complete, limiting its usefulness.18
Positron emission tomography using fluorodeoxyglucose F 18 may also help differentiate malignant from benign adrenal lesions in patients with proven or suspected malignancy. The test is nearly 100% sensitive and 94% to 95% specific. Because it is expensive and not widely available, it is not recommended for routine evaluation of adrenal incidentalomas.

Fine-needle aspiration biopsy
Cytologic study of a specimen obtained by imaging-guided fine-needle aspiration may help in evaluating an adrenal mass suspected of being metastatic that has a noncontrast CT attenuation value of more than 10 HU. It cannot, however, always differentiate an adrenocortical carcinoma from an adrenal adenoma.

To avoid causing a possible hypertensive crisis, pheochromocytoma should always be excluded before fine-needle aspiration of an adrenal mass is attempted.

Is it functional?

From 6% to 20% of patients with adrenal incidentalomas have hormonal abnormalities, showing that the mass is functional. Hormonal hypersecretion is most likely with masses that are at least 3 cm in diameter, and it occurs mostly within the first 3 years after diagnosis.

A careful personal and family history, review of systems, and physical examination should be performed in all patients. In addition, patients should be evaluated—at a minimum—for the following conditions:

- Pheochromocytoma
- Cushing syndrome (including subclinical disease)
- Primary aldosteronism (only if hypertensive).

Pheochromocytoma
Up to 11% of adrenal incidentalomas are pheochromocytomas. Screening for pheochromocytoma is mandatory in all cases because of this condition’s high rates of morbidity and mortality, as well as because of its unpredictable course. It is completely asymptomatic in up to 15% of cases.

An appropriate initial screening test is measurement of plasma free metanephrines or 24-hour urine metanephrines. Clinicians should be familiar with the diagnostic characteristics of the assay they use.

Measurement of plasma free metanephrines is 99% sensitive for sporadic cases of pheochromocytoma, so from a practical standpoint, a normal value rules it out. But this test has a false-positive rate of 10% to 15%, so a positive result warrants either further testing of 24-hour urine metanephrines or a clonidine suppression test, depending on the clinical picture.

Cushing syndrome
Most patients with autonomous cortisol-secreting cortical adenomas do not have the typical signs and symptoms of Cushing syndrome. However, from 5% to 20% of patients with adrenal incidentalomas are reported to have subclinical Cushing syndrome. The estimate varies greatly, depending on diagnostic criteria and screening methods, since subclinical Cushing syndrome is still poorly defined. These patients are reported to have an increased frequency of hypertension, glucose intolerance, diabetes, and possibly osteopenia compared with the general population.

In 2002, a National Institutes of Health consensus panel recommended a 1-mg overnight dexamethasone suppression test for initial biochemical evaluation of adrenal incidentalomas. In this test, dexamethasone 1 mg is given at 11 PM and the cortisol level is measured at 8 AM; a normal result is less than 5.0 µg/dL of cortisol. We agree with this recommendation, but with a lower threshold: we would recommend further workup if the dexamethasone challenge does not suppress the patient’s cortisol level to less than 1.8 µg/dL. At this level, the main value of the test is to rule out Cushing syndrome, but a positive test does not confirm the diagnosis because false-positives do occur.

An apparent lack of suppression can be caused by a number of interfering conditions, including:

- Decreased dexamethasone absorption
- Drugs that enhance hepatic dexamethasone metabolism (barbiturates, phenytoin, carbamazepine, rifampicin)
Increased concentration of corticosteroid-binding globulin (from estrogens or pregnancy)

Pseudo-Cushing states. Estimating the plasma concentration of dexamethasone may be useful in special situations to ensure that an adequate level of dexamethasone is present, but it is not indicated for routine testing.

To diagnose subclinical Cushing syndrome, a reasonable approach is to require at least two of the following abnormal results of tests of the hypothalamo-pituitary-adrenal axis:

- Lack of cortisol suppression during a 1-mg overnight dexamethasone suppression test
- Increased urinary free cortisol levels
- Loss of diurnal cortisol rhythm
- Low or suppressed corticotropin (ACTH) level
- Impaired ACTH response to corticotropin-releasing hormone.

The midnight salivary cortisol level is another helpful test.

**Primary aldosteronism**

From 1.6% to 3.8% of adrenal incidentalomas are aldosterone-secreting adenomas. Only patients with hypertension should be evaluated for primary aldosteronism.

Hypokalemia in a patient with hypertension suggests aldosteronism, but normokalemia does not exclude it.

The best screening test is the ratio of the ambulatory plasma aldosterone concentration to the plasma renin activity. Plasma should be sampled in the morning. The test can be done in patients taking any antihypertensive medications except spironolactone or eplerenone. A ratio of 20 or greater along with a plasma aldosterone concentration above 10 ng/dL needs to be further evaluated by measuring 24-hour urine aldosterone during salt loading.

A very low plasma renin activity level using a highly sensitive assay can result in an
elevated ratio, even if aldosterone is in the low normal range. Changes in position, diuretic therapy, and serum aldosterone levels may also affect the ratio.

Laboratories that use the direct renin assay should use a different ratio as a criterion because direct renin level is about 8 times higher than plasma renin activity.

Androgen-secreting tumors
Isolated androgen-secreting adrenal adenomas are rare, but levels of androgens or their precursors may be high in patients with adrenocortical carcinoma. Patients usually have symptoms related to hormonal hypersecretion, so screening for sex-hormone excess is unnecessary if clinical features are absent. Women with an adrenal mass and physical findings suggestive of hyperandrogenism should have their total testosterone and dehydroepiandrosterone sulfate levels measured.7

CASE REVISITED

Our patient undergoes hormonal evaluation. The results are as follows:
- Plasma free metanephrines < 0.20 nmol/L (normal < 0.50)
- Plasma free normetanephrines 0.37 nmol/L (normal < 0.90)
- 8 AM serum cortisol after 1-mg dexamethasone suppression 2.4 µg/dL (normal < 1.8)
- Plasma aldosterone 7.1 ng/dL (normal 4.5–35.4)
- Plasma renin, direct 11.7 µU/mL (normal 2.4–29).

Because the overnight dexamethasone suppression test is abnormal, he undergoes further testing for subclinical Cushing syndrome. His findings are as follows:
- 24-hour urine free cortisol 18.7 µg/24 hours (normal 20–100)
- Morning plasma ACTH 23 pg/mL (normal 5–50)
- Midnight salivary cortisol 15 ng/dL (normal < 100).

Because the tests of the hypothalamo-pituitary-adrenal axis are normal, we conclude that the initial abnormal 1-mg overnight dexamethasone suppression test was likely falsely positive. The patient is scheduled for follow-up in 6 months.

OUR ALGORITHM

Our approach to evaluating adrenal incidentalomas is shown in FIGURE 3.

If the mass is functional or malignant, we usually refer for surgery.

If the noncontrast CT attenuation value is 10 HU or less and the mass is nonfunctional, we do not routinely obtain any follow-up imaging study. However, annual evaluation for hormonal hypersecretion is recommended, especially if the mass is larger than 3 cm.13,37 How long follow-up should continue is unknown, and further long-term studies are needed to determine this. The incidence of new hormonal hypersecretion may plateau after 5 years.13 The likelihood of primary adrenocortical carcinoma developing from an adenomatous or hyperplastic adrenal mass is not known, but it seems to be extremely rare.13,38,39

If the noncontrast CT attenuation value is greater than 10 HU and the mass measures 6 cm or more, we would refer the patient for surgery. For smaller nonfunctional masses, we obtain the enhancement washout percentage at 15 minutes: if less than 60%, we also refer the patient for surgery. However, this recommendation needs to be further evaluated and confirmed in large studies. If the enhancement washout is 60% or more, patients should have
a follow-up imaging study in 6 to 12 months and have the mass resected if it grows by more than 1 cm. No good evidence supports continuing radiologic surveillance if the first follow-up study shows no change in tumor size.\textsuperscript{7}

If the mass is either functional or malignant, patients are usually referred for surgery. But medical therapy may be acceptable for primary aldosteronism that is secondary to adrenocortical adenoma or hyperplasia. Also, surgery is usually not indicated if malignancy is widespread; any surgical intervention should be pursued only if the patient would benefit.

Compared with open adrenalectomy, laparoscopic surgery results in less postoperative pain, a quicker return of bowel function, a shorter hospital stay, and earlier return to work.\textsuperscript{40} Surgeons who are more experienced tend to obtain better results.

\section*{REFERENCES}


\section*{CASE CONCLUDED}

Our patient has a repeat CT scan (with and without contrast) after 6 months, which shows a nodule in the left adrenal gland measuring 2.2 by 1.3 cm, unchanged in size. On the precontrast scan, the mean attenuation value is 40 HU (Figure 4). However, 2 minutes after he receives intravenous contrast, the attenuation value is 96 HU and at 15 minutes it is 51. This represents an 80% enhancement washout, suggestive of a lipid-poor adrenal adenoma.

The patient is determined to have an adrenal mass that is hormonally silent with no change in size on 6-month follow-up and with CT characteristics of a benign tumor. He is advised to return in 1 year for evaluation of hormonal hypersecretion.


ADDRESS: Amir H. Hamrahian, MD, Department of Endocrinology, Diabetes, and Metabolism, A53, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail hamrahia@ccf.org.